Baseline patient characteristics and select transplant outcomes in pediatric patients undergoing URD HCT for NMD with with Aba GVHD prophylaxis
| Patient ID . | Age, y . | Sex . | Indication . | Conditioning . | Donor . | TNC per kg . | CD34+ cells per kg . | CMV D/R . | Recipient EBV . | ABO D/R . | Time to ANC ≥ 500, d . | Time to plts ≥ 20, d . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 6 | F | DBA | rATGFluCyTBI | 8/8 | 3.3E + 08 | 2E + 06 | IC/− | − | A+/O− | 19 | 34 |
| 2 | 8 | M | FA | rATGFluCy | 7/8 | 5.3E + 08 | 3.4E + 06 | −/− | + | O+/O+ | 15 | 15 |
| 3 | 11 | M | SAA | rATGFluCyTBI | 7/8 | 1.6E + 08 | 9.7E + 06 | −/− | + | A+/O+ | 20 | 16 |
| 4 | 6 | F | SAA | rATGFluCyTBI | 7/8 | 5.7E + 08 | 7.8E + 06 | −/− | − | O+/A− | 22 | 11 |
| 5 | 2 | M | CDA | rATGFluCyTBI | 8/8 | 4.4E + 08 | 1.3E + 07 | −/+ | + | A+/O+ | 20 | 25 |
| 6 | 6 | M | FA | rATGFluCy | 8/8 | 1.7E + 08 | 6E + 06 | +/− | _ | O+/A+ | 22 | 20 |
| 7 | 18 | F | SAA | rATGFluCyTBI | 7/8 | 5.7E + 07 | 3.8E + 06 | +/+ | + | B+/A+ | N/A | N/A |
| 8 | 5 | M | FA | rATGFluCy | 7/8 | 6.1E + 08 | 9E + 06 | +/− | + | O+/O+ | 15 | 17 |
| 9 | 9 | M | SCN | AlemFluTTMel | 8/8 | 3.8E + 08 | 6.3E + 06 | −/− | − | O+/O+ | 20 | 16 |
| 10 | 0.5 | F | CAMT | AlemFluTTMel | 8/8 | 7.6E + 08 | 9E + 06 | +/+ | + | O+/O+ | 22 | 15 |
| Patient ID . | Age, y . | Sex . | Indication . | Conditioning . | Donor . | TNC per kg . | CD34+ cells per kg . | CMV D/R . | Recipient EBV . | ABO D/R . | Time to ANC ≥ 500, d . | Time to plts ≥ 20, d . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 6 | F | DBA | rATGFluCyTBI | 8/8 | 3.3E + 08 | 2E + 06 | IC/− | − | A+/O− | 19 | 34 |
| 2 | 8 | M | FA | rATGFluCy | 7/8 | 5.3E + 08 | 3.4E + 06 | −/− | + | O+/O+ | 15 | 15 |
| 3 | 11 | M | SAA | rATGFluCyTBI | 7/8 | 1.6E + 08 | 9.7E + 06 | −/− | + | A+/O+ | 20 | 16 |
| 4 | 6 | F | SAA | rATGFluCyTBI | 7/8 | 5.7E + 08 | 7.8E + 06 | −/− | − | O+/A− | 22 | 11 |
| 5 | 2 | M | CDA | rATGFluCyTBI | 8/8 | 4.4E + 08 | 1.3E + 07 | −/+ | + | A+/O+ | 20 | 25 |
| 6 | 6 | M | FA | rATGFluCy | 8/8 | 1.7E + 08 | 6E + 06 | +/− | _ | O+/A+ | 22 | 20 |
| 7 | 18 | F | SAA | rATGFluCyTBI | 7/8 | 5.7E + 07 | 3.8E + 06 | +/+ | + | B+/A+ | N/A | N/A |
| 8 | 5 | M | FA | rATGFluCy | 7/8 | 6.1E + 08 | 9E + 06 | +/− | + | O+/O+ | 15 | 17 |
| 9 | 9 | M | SCN | AlemFluTTMel | 8/8 | 3.8E + 08 | 6.3E + 06 | −/− | − | O+/O+ | 20 | 16 |
| 10 | 0.5 | F | CAMT | AlemFluTTMel | 8/8 | 7.6E + 08 | 9E + 06 | +/+ | + | O+/O+ | 22 | 15 |
Alem, alemtuzumab; ANC, absolute neutrophil count; CAMT, congenital amegakaryocytic thrombocytopenia; CDA, congenital dyserythropoietic anemia; Cy, cyclophosphamide; DBA, Diamond-Blackfan anemia; D/R, donor/recipient; F, female; Flu, fludarabine; IC, inconclusive; M, male; Mel, melphalan; N/A, not applicable; plts, platelets; rATG, rabbit antithymocyte globulin; SCN, severe congenital anemia; TBI, total body irradiation; TT, thiotepa.